Third Harmonic Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Third Harmonic Bio Reports Full Year 2024 Results, Outlines Strategic Review and Restructuring
Third Harmonic Bio announces its full year 2024 financial results, a strategic review process, and a restructuring plan involving a 50% workforce reduction.
Third Harmonic Bio's 10-K filing details the company's focus on developing oral KIT inhibitors for inflammatory diseases, including the planned initiation of clinical studies for THB335 in Q2 2024.